177 related articles for article (PubMed ID: 26179454)
1. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
Grunberger G; Forst T; Fernández Landó L; Pechtner V; Shaginian R; Jia N; Gough S
Diabet Med; 2016 Mar; 33(3):391-4. PubMed ID: 26179454
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
3. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
Umpierrez GE; Pantalone KM; Kwan AY; Zimmermann AG; Zhang N; Fernández Landó L
Diabetes Obes Metab; 2016 Jun; 18(6):615-22. PubMed ID: 26969812
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
5. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
6. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
7. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
Wysham C; Guerci B; D'Alessio D; Jia N; Botros FT
Diabetes Obes Metab; 2016 Nov; 18(11):1138-1142. PubMed ID: 27265893
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
Araki E; Inagaki N; Tanizawa Y; Oura T; Takeuchi M; Imaoka T
Diabetes Obes Metab; 2015 Oct; 17(10):994-1002. PubMed ID: 26179754
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
Morioka T; Takeuchi M; Ozeki A; Emoto M
Diabetes Obes Metab; 2024 Aug; 26(8):3167-3175. PubMed ID: 38715179
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
Chen YH; Huang CN; Cho YM; Li P; Gu L; Wang F; Yang J; Wang WQ
Diabetes Obes Metab; 2018 Sep; 20(9):2121-2130. PubMed ID: 29708650
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
18. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
[TBL] [Abstract][Full Text] [Related]
19. Dulaglutide for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
Li H; Xu X; Wang J; Kong X; Chen M; Jing T; Zhang Z; Yin G; Liu X; Hu Y; Ye L; Su X; Ma J
J Diabetes Res; 2019; 2019():6423987. PubMed ID: 31183384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
